Teclistamab is a bispecific antibody approved by the FDA in October 2022 that targets the B-cell maturation antigen (BCMA) found on the surface of myeloma cells. It essentially recruits the body's immune system to attack and destroy these cancer cells.

Indication (Who Can Receive It)

Teclistamab is intended for patients with multiple myeloma that has progressed (relapsed) after receiving at least four prior lines of therapy, including at least one immunomodulatory agent (like lenalidomide or pomalidomide), one proteasome inhibitor (like bortezomib or carfilzomib), and one anti-CD38 monoclonal antibody (like daratumumab or isatuximab).

Administration

Teclistamab is given subcutaneously (via injection), once weekly. This is currently the only bispecific antibody whose dosing is based off of your body weight.

Frequency

Patients who have maintained a complete response on teclistimab for at least six months may be eligible for a reduced dosage administered every other week.

Side Effects and Adverse Events 

As reported in teclistamab’s clinical trials, 72% of patients experienced some grade of CRS and 57% some grade of neurologic toxicities, including ICANS. Additionally, 84% of patients receiving teclistamab experienced low numbers of a specific type of white blood cell (called a neutrophil), a condition known as neutropenia which raises the risk for serious infections. Read more about teclistamab's safety profile. 

Percentage and Duration of Response 

63% of patients treated with teclistamab achieved at least a partial response or better (with 28% of patients achieving a complete response).

For patients who had at least a partial response or better, the median duration of response was 11.4 months. For patients who had at least a very good partial response or better, the median duration of response was 26.7 months.

For more information on teclistamab, visit tecvayli.com